Caffeine, nicotinic acid, nux vomica
Sold as Force x
Every registration of this product has been cancelled.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Astley Laboratories S.A (Pty) LtdCancelled | Force x | Not stated | G2545 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Force x TABLET CAFFEINE A 60 MG NICOTINIC ACID A 25 MG NUX VOMICA A 8 MG | Not listed | G2545 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Niacin
- when intended for hypercholesterolaemia and for the management of dyslipidaemias; (S0)
- except in oral preparations or mixtures containing more than 35 mg of Niacin per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)
Consolidated Schedules 06 July 2026, lines 7247 to 7252
S3: Caffeine
- when intended for injection.
Consolidated Schedules 06 July 2026, line 3256
S2: Nux vomica
- substances, preparations and mixtures thereof, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).
Consolidated Schedules 06 July 2026, lines 2435 to 2436
S1: Niacin
- in oral preparations or mixtures containing more than 35 mg of Niacin per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
- except when intended for hypercholesterolaemia and for the management of dyslipidaemias. (S4)
Consolidated Schedules 06 July 2026, lines 879 to 884
1 of 10 approved products with this ingredient carry S5 on their leaflet.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.